688192 迪哲医药
已收盘 04-30 15:00:01
资讯
新帖
简况
每周股票复盘：迪哲医药（688192）股东户数增8.82%，一季报营收增58.18%
证券之星 · 05-02 06:41
每周股票复盘：迪哲医药（688192）股东户数增8.82%，一季报营收增58.18%
迪哲医药(688192)3月31日股东户数1.09万户，较上期增加8.82%
证券之星 · 04-29
迪哲医药(688192)3月31日股东户数1.09万户，较上期增加8.82%
股市必读：4月24日迪哲医药现1笔折价16.03%的大宗交易 合计成交2222.66万元
证券之星 · 04-27
股市必读：4月24日迪哲医药现1笔折价16.03%的大宗交易 合计成交2222.66万元
每周股票复盘：迪哲医药（688192）多款肺癌药研究入选ASCO大会
证券之星 · 04-26
每周股票复盘：迪哲医药（688192）多款肺癌药研究入选ASCO大会
迪哲医药(688192.SH)：多项肺癌领域研究成果获选2026年美国临床肿瘤学会(ASCO)大会报告
智通财经 · 04-22
迪哲医药(688192.SH)：多项肺癌领域研究成果获选2026年美国临床肿瘤学会(ASCO)大会报告
迪哲医药（688192）披露2025年年度股东会会议资料，4月15日股价上涨3.95%
证券之星 · 04-15
迪哲医药（688192）披露2025年年度股东会会议资料，4月15日股价上涨3.95%
每周股票复盘：迪哲医药（688192）2025年主营收入8.01亿元
证券之星 · 04-05
每周股票复盘：迪哲医药（688192）2025年主营收入8.01亿元
图解迪哲医药年报：第四季度单季净利润同比增长35.96%
证券之星 · 03-31
图解迪哲医药年报：第四季度单季净利润同比增长35.96%
迪哲医药（688192）披露舒沃哲一线治疗EGFR PACC或其他罕见突变非小细胞肺癌最新数据，3月30日股价下跌0.71%
证券之星 · 03-30
迪哲医药（688192）披露舒沃哲一线治疗EGFR PACC或其他罕见突变非小细胞肺癌最新数据，3月30日股价下跌0.71%
迪哲医药公布最新临床试验结果；安徽质子治疗费大幅降价
21世纪经济报道 · 03-23
迪哲医药公布最新临床试验结果；安徽质子治疗费大幅降价
迪哲医药(688192.SH)：舒沃哲®单药一线治疗EGFRexon20ins非小细胞肺癌国际多中心III期临床试验获阳性顶线结果
智通财经 · 03-22
迪哲医药(688192.SH)：舒沃哲®单药一线治疗EGFRexon20ins非小细胞肺癌国际多中心III期临床试验获阳性顶线结果
每周股票复盘：迪哲医药（688192）现溢价19.21%大宗交易
证券之星 · 03-22
每周股票复盘：迪哲医药（688192）现溢价19.21%大宗交易
3月19日迪哲医药现1笔溢价19.21%的大宗交易 合计成交333.42万元
证券之星 · 03-19
3月19日迪哲医药现1笔溢价19.21%的大宗交易 合计成交333.42万元
新股消息 | 迪哲医药(688192.SH)拟港股上市 中国证监会要求补充说明董事与高管相互之间存在的关联关系等
智通财经网 · 03-13
新股消息 | 迪哲医药(688192.SH)拟港股上市 中国证监会要求补充说明董事与高管相互之间存在的关联关系等
迪哲医药跌3% 2021年上市中信证券保荐2募资共39亿
中金财经 · 03-12
迪哲医药跌3% 2021年上市中信证券保荐2募资共39亿
每周股票复盘：迪哲医药（688192）提前归还10,336.33万元闲置募资
证券之星 · 03-08
每周股票复盘：迪哲医药（688192）提前归还10,336.33万元闲置募资
迪哲医药（688192）披露关于提前归还临时补充流动资金的闲置募集资金的公告，3月6日股价上涨4.53%
证券之星 · 03-06
迪哲医药（688192）披露关于提前归还临时补充流动资金的闲置募集资金的公告，3月6日股价上涨4.53%
股市必读：迪哲医药发布2025年度业绩快报，亏损7.633亿元
证券之星 · 03-02
股市必读：迪哲医药发布2025年度业绩快报，亏损7.633亿元
每周股票复盘：迪哲医药（688192）2025年营收增122.60%
证券之星 · 03-01
每周股票复盘：迪哲医药（688192）2025年营收增122.60%
迪哲医药（688192）披露2025年度业绩快报公告，2月27日股价上涨1.17%
证券之星 · 02-27
迪哲医药（688192）披露2025年度业绩快报公告，2月27日股价上涨1.17%
加载更多
公司概况
公司名称：
迪哲(江苏)医药股份有限公司
所属行业：
医药制造业
上市日期：
2021-12-10
主营业务：
迪哲(江苏)医药股份有限公司的主营业务是专注于肿瘤、血液系统疾病领域创新疗法的研究、开发和商业化。公司的主要产品是舒沃哲、高瑞哲。公司获第七批国家级专精特新“小巨人”企业认定。此外，公司首款源头创新产品舒沃哲的研发及产业化项目，荣获江苏省科技进步奖一等奖。
发行价格：
52.58
{"stockData":{"symbol":"688192","market":"SH","secType":"STK","nameCN":"迪哲医药","latestPrice":56.7,"timestamp":1777532401000,"preClose":55.53,"halted":0,"volume":4009424,"delay":0,"changeRate":0.0211,"floatShares":461000000,"shares":465000000,"eps":-1.4341,"marketStatus":"已收盘","change":1.17,"latestTime":"04-30 15:00:01","open":56.2,"high":59.1,"low":56.2,"amount":231000000,"amplitude":0.0522,"askPrice":56.7,"askSize":251,"bidPrice":56.62,"bidSize":42,"shortable":0,"etf":0,"ttmEps":-1.4341,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1778031000000},"marketStatusCode":5,"adr":0,"adjPreClose":55.53,"symbolType":"stock_kcb","openAndCloseTimeList":[[1777512600000,1777519800000],[1777525200000,1777532400000]],"highLimit":61.08,"lowLimit":49.98,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":465165842,"isCdr":false,"pbRate":21.37,"roa":"--","roe":"--","epsLYR":-1.71,"committee":-0.605701,"marketValue":26375000000,"turnoverRate":0.0087,"status":0,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-05-06。","afterMarket":{"amount":0,"volume":0,"close":56.7,"buyVolume":0,"sellVolume":0,"time":1777534437559,"indexStatus":"已收盘 04-30 15:30:00","preClose":55.53},"floatMarketCap":26151000000},"requestUrl":"/m/hq/s/688192","defaultTab":"news","newsList":[{"id":"2632258706","title":"每周股票复盘：迪哲医药（688192）股东户数增8.82%，一季报营收增58.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2632258706","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632258706?lang=zh_cn&edition=full","pubTime":"2026-05-02 06:41","pubTimestamp":1777675268,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，迪哲医药报收于56.7元，较上周的55.6元上涨1.98%。本周，迪哲医药4月30日盘中最高价报59.1元。迪哲医药当前最新总市值263.75亿元，在化学制药板块市值排名17/150，在两市A股市值排名829/5200。业绩披露要点财务报告迪哲医药2026年一季报显示，一季度公司主营收入2.53亿元，同比上升58.18%；归母净利润-9555.74万元，同比上升50.36%；扣非净利润-1.09亿元，同比上升50.41%；负债率59.01%，财务费用712.85万元，毛利率95.92%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050200003628.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688192"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631596344","title":"迪哲医药(688192)3月31日股东户数1.09万户，较上期增加8.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631596344","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631596344?lang=zh_cn&edition=full","pubTime":"2026-04-29 17:42","pubTimestamp":1777455773,"startTime":"0","endTime":"0","summary":"证券之星消息，近日迪哲医药披露，截至2026年3月31日公司股东户数为1.09万户，较2月28日增加883.0户，增幅为8.82%。在化学制药行业个股中，迪哲医药股东户数低于行业平均水平，截至3月31日，化学制药行业平均股东户数为3.6万户。从股价来看，2026年2月28日至2026年3月31日，迪哲医药区间涨幅为6.46%，在此期间股东户数增加883.0户，增幅为8.82%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042900055379.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688192","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630833933","title":"股市必读：4月24日迪哲医药现1笔折价16.03%的大宗交易 合计成交2222.66万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2630833933","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630833933?lang=zh_cn&edition=full","pubTime":"2026-04-27 04:21","pubTimestamp":1777234869,"startTime":"0","endTime":"0","summary":"截至2026年4月24日收盘，迪哲医药报收于55.6元，下跌2.15%，换手率0.62%，成交量2.88万手，成交额1.61亿元。交易信息汇总资金流向4月24日主力资金净流出1087.1万元，占总成交额6.73%；游资资金净流出874.81万元，占总成交额5.42%；散户资金净流入1961.91万元，占总成交额12.15%。大宗交易4月24日迪哲医药现1笔折价16.03%的大宗交易，合计成交2222.66万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042700005809.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688192"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630804520","title":"每周股票复盘：迪哲医药（688192）多款肺癌药研究入选ASCO大会","url":"https://stock-news.laohu8.com/highlight/detail?id=2630804520","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630804520?lang=zh_cn&edition=full","pubTime":"2026-04-26 03:38","pubTimestamp":1777145892,"startTime":"0","endTime":"0","summary":"截至2026年4月24日收盘，迪哲医药报收于55.6元，较上周的59.06元下跌5.86%。本周，迪哲医药4月20日盘中最高价报60.19元。本周关注点交易信息汇总：4月23日及24日迪哲医药连续两日出现折价超16%的大宗交易。4月23日迪哲医药发生1笔折价16.3%的大宗交易，合计成交3376.76万元。公司公告汇总迪哲医药自愿披露，其自主研发产品舒沃哲、高瑞哲及DZD6008在非小细胞肺癌领域的多项研究成果获选2026年美国临床肿瘤学会大会报告。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042600001517.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688192"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629006195","title":"迪哲医药(688192.SH)：多项肺癌领域研究成果获选2026年美国临床肿瘤学会(ASCO)大会报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2629006195","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629006195?lang=zh_cn&edition=full","pubTime":"2026-04-22 07:57","pubTimestamp":1776815821,"startTime":"0","endTime":"0","summary":"智通财经APP讯， 迪哲医药 发布公告，公司将在2026 年5月29日至6月2日于芝加哥举行的美国临床肿瘤学会年会上，公布其自主研发产品舒沃哲、高瑞哲以及DZD6008在非小细胞肺癌领域的最新研究成果，其中2项将以口头报告形式公布。此外，公司还将在大会上公布一项高瑞哲联合抗PD-1抗体一线治疗无驱动基因突变NSCLC的最新研究进展。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1431656.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688192","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627407694","title":"迪哲医药（688192）披露2025年年度股东会会议资料，4月15日股价上涨3.95%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627407694","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627407694?lang=zh_cn&edition=full","pubTime":"2026-04-15 17:05","pubTimestamp":1776243940,"startTime":"0","endTime":"0","summary":"截至2026年4月15日收盘，迪哲医药报收于60.2元，较前一交易日上涨3.95%，最新总市值为280.03亿元。该股当日开盘59.5元，最高60.98元，最低57.0元，成交额达3.21亿元，换手率为1.17%。迪哲医药于2026年4月15日披露《2025年年度股东会会议资料》。公司2025年度实现营业收入8.01亿元，同比增长122.60%，首次实现商业化盈利，但因累计未分配利润为负，2025年度不进行利润分配。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041500030394.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688192"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625619913","title":"每周股票复盘：迪哲医药（688192）2025年主营收入8.01亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2625619913","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625619913?lang=zh_cn&edition=full","pubTime":"2026-04-05 03:07","pubTimestamp":1775329631,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘，迪哲医药报收于57.5元，较上周的56.0元上涨2.68%。本周，迪哲医药4月2日盘中最高价报59.56元。本周关注点来自业绩披露要点：迪哲医药2025年主营收入8.01亿元，同比上升122.6%。业绩披露要点财务报告迪哲医药2025年年报显示，公司主营收入8.01亿元，同比上升122.6%；归母净利润-7.64亿元，同比上升9.68%；扣非净利润-8.42亿元，同比上升6.38%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040500000848.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688192"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623932334","title":"图解迪哲医药年报：第四季度单季净利润同比增长35.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623932334","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623932334?lang=zh_cn&edition=full","pubTime":"2026-03-31 02:01","pubTimestamp":1774893665,"startTime":"0","endTime":"0","summary":"证券之星消息，迪哲医药2025年年报显示，当年度公司主营收入8.01亿元，同比上升122.6%；归母净利润-7.64亿元，同比上升9.68%；扣非净利润-8.42亿元，同比上升6.38%；其中2025年第四季度，公司单季度主营收入2.15亿元，同比上升901.58%；单季度归母净利润-1.84亿元，同比上升35.96%；单季度扣非净利润-2.11亿元，同比上升29.55%；负债率56.85%，财务费用3019.1万元，毛利率95.73%。财报数据概要请见下图:以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026033100004829.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688192"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623313166","title":"迪哲医药（688192）披露舒沃哲一线治疗EGFR PACC或其他罕见突变非小细胞肺癌最新数据，3月30日股价下跌0.71%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623313166","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623313166?lang=zh_cn&edition=full","pubTime":"2026-03-30 17:29","pubTimestamp":1774862990,"startTime":"0","endTime":"0","summary":"截至2026年3月30日收盘，迪哲医药报收于55.6元，较前一交易日下跌0.71%，最新总市值为258.34亿元。近日，迪哲医药发布自愿披露公告，舒沃哲在2026年欧洲肺癌大会上发布一线治疗EGFR PACC或其他罕见突变非小细胞肺癌的最新数据。15例基线脑转移患者中有11例肿瘤缓解，6例确认部分缓解。中位缓解持续时间未达到，81.3%患者仍在治疗，6个月持续缓解率预估87.5%。9个月无进展生存率预估83.9%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026033000024038.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688192"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621740280","title":"迪哲医药公布最新临床试验结果；安徽质子治疗费大幅降价","url":"https://stock-news.laohu8.com/highlight/detail?id=2621740280","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621740280?lang=zh_cn&edition=full","pubTime":"2026-03-23 09:07","pubTimestamp":1774228034,"startTime":"0","endTime":"0","summary":"政策动向商务部：在部分有条件的地区探索建设国际医疗旅游集聚区3月20日，商务部发布《关于促进旅行服务出口扩大入境消费的政策措施》。在部分有条件的地区探索建设国际医疗旅游集聚区，面向国际患者提供高端体检、整形美容、康复护理等服务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603233679899856.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603233679899856.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["688192","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621719302","title":"迪哲医药(688192.SH)：舒沃哲®单药一线治疗EGFRexon20ins非小细胞肺癌国际多中心III期临床试验获阳性顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2621719302","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621719302?lang=zh_cn&edition=full","pubTime":"2026-03-22 15:43","pubTimestamp":1774165425,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迪哲医药(688192.SH)公告，公司自主研发的产品舒沃哲®(ZEGFROVY®，通用名：舒沃替尼片)单药一线治疗表皮生长因子受体(EGFR)20号外显子插入突变(exon20ins)晚期非小细胞肺癌(NSCLC)的国际多中心III期临床研究“悟空28”(WU-KONG28)达到主要研究终点、取得阳性顶线结果，是全球首个且唯一在国际多中心随机对照III期临床研究中，针对EGFRexon20ins NSCLC一线治疗取得阳性结果的口服靶向药物。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417047.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["III","BK4134","BK0239","688192"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621088799","title":"每周股票复盘：迪哲医药（688192）现溢价19.21%大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2621088799","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621088799?lang=zh_cn&edition=full","pubTime":"2026-03-22 03:14","pubTimestamp":1774120450,"startTime":"0","endTime":"0","summary":"截至2026年3月20日收盘，迪哲医药报收于48.64元，较上周的48.23元上涨0.85%。本周，迪哲医药3月17日盘中最高价报52.33元。3月16日盘中最低价报47.6元。迪哲医药当前最新总市值226.0亿元，在化学制药板块市值排名18/150，在两市A股市值排名901/5190。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032200001229.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688192"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620245866","title":"3月19日迪哲医药现1笔溢价19.21%的大宗交易 合计成交333.42万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2620245866","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620245866?lang=zh_cn&edition=full","pubTime":"2026-03-19 17:20","pubTimestamp":1773912047,"startTime":"0","endTime":"0","summary":"证券之星消息，3月19日迪哲医药发生大宗交易，交易数据如下：大宗交易成交价格59.19元，相对当日收盘价溢价19.21%，成交5.63万股，成交金额333.42万元，买方营业部为方正证券股份有限公司重庆金开大道证券营业部，卖方营业部为西南证券股份有限公司重庆第四分公司。近三个月该股共发生1笔大宗交易，合计成交563.0手，溢价成交1笔。截至2026年3月19日收盘，迪哲医药报收于49.65元，下跌2.11%，换手率0.37%，成交量1.68万手，成交额8444.1万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031900028128.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688192","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619194222","title":"新股消息 | 迪哲医药(688192.SH)拟港股上市 中国证监会要求补充说明董事与高管相互之间存在的关联关系等","url":"https://stock-news.laohu8.com/highlight/detail?id=2619194222","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619194222?lang=zh_cn&edition=full","pubTime":"2026-03-13 19:42","pubTimestamp":1773402144,"startTime":"0","endTime":"0","summary":"中国证监会发布《境外发行上市备案补充材料要求(2026年3月3日—2026年3月13日)》。中国证监会国际司共对8家企业出具补充材料要求，其中，要求迪哲医药补充说明董事、高级管理人员相互之间存在的关联关系情况等事项。","market":"us","thumbnail":"https://img.zhitongcaijing.com/image/20260313/20260313194246_25749.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260313/20260313194246_25749.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1413794.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["VXUS","BK0239","BK4585","688192","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618318432","title":"迪哲医药跌3% 2021年上市中信证券保荐2募资共39亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2618318432","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618318432?lang=zh_cn&edition=full","pubTime":"2026-03-12 16:33","pubTimestamp":1773304391,"startTime":"0","endTime":"0","summary":"中国经济网北京3月12日讯 迪哲医药 今日收报49.19元，跌幅3.00%，总市值228.55亿元。该股目前处于破发状态。 迪哲医药于2021年12月10日在上交所科创板上市，发行股票4000.01万股，发行价格为52.58元/股。 迪哲医药首次公开发行股票募集资金总额为21.03亿元，扣除发行费用后募集资金净额为19.87亿元。迪哲医药最终募集资金净额比原计划多2.03亿元。 迪哲医药2次募资合计募集资金38.99亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260312/32063314.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["LU2289578879.USD","LU1997245177.USD","BK0183","LU0405327148.USD","LU1064130708.USD","BK0012","BK1564","LU1064131003.USD","BK0196","LU1655091616.SGD","BK0028","BK0239","LU1255011170.USD","LU2495084118.USD","LU1328615791.USD","06030","LU1997245094.SGD","BK1147","LU1794554557.SGD","BK0276","BK1521","LU1997244956.HKD","688192","BK0188","LU2148510915.USD","BK1516","LU0405327494.USD","600030","LU1720050803.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617668742","title":"每周股票复盘：迪哲医药（688192）提前归还10,336.33万元闲置募资","url":"https://stock-news.laohu8.com/highlight/detail?id=2617668742","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617668742?lang=zh_cn&edition=full","pubTime":"2026-03-08 02:22","pubTimestamp":1772907732,"startTime":"0","endTime":"0","summary":"截至2026年3月6日收盘，迪哲医药报收于50.75元，较上周的50.9元下跌0.29%。本周，迪哲医药3月6日盘中最高价报51.57元。本周关注点公司公告汇总：迪哲医药已提前全额归还临时补充流动资金的10,336.33万元闲置募集资金。公司实际使用10,336.33万元，截至2026年3月6日已将该款项全部提前归还至募集资金专用账户，使用期限未超过董事会批准期限，并已通知保荐机构和保荐代表人。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030800000708.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688192"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617636553","title":"迪哲医药（688192）披露关于提前归还临时补充流动资金的闲置募集资金的公告，3月6日股价上涨4.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617636553","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617636553?lang=zh_cn&edition=full","pubTime":"2026-03-06 22:36","pubTimestamp":1772807780,"startTime":"0","endTime":"0","summary":"截至2026年3月6日收盘，迪哲医药报收于50.75元，较前一交易日上涨4.53%，最新总市值为235.8亿元。该股当日开盘48.55元，最高51.57元，最低48.37元，成交额达1.5亿元，换手率为0.64%。近日，迪哲（江苏）医药股份有限公司发布《关于提前归还临时补充流动资金的闲置募集资金的公告》。公司实际使用10,336.33万元，截至2026年3月6日已将该款项全部提前归还至募集资金专用账户，使用期限未超过董事会批准期限，并已通知保荐机构和保荐代表人。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030600040448.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688192","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616875004","title":"股市必读：迪哲医药发布2025年度业绩快报，亏损7.633亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2616875004","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616875004?lang=zh_cn&edition=full","pubTime":"2026-03-02 02:36","pubTimestamp":1772390173,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘，迪哲医药报收于50.9元，上涨1.17%，换手率0.3%，成交量1.4万手，成交额7101.84万元。来自业绩披露要点：迪哲医药预计2025年归属净利润亏损7.633亿元，同比减亏9.77%。来自公司公告汇总：迪哲医药发布2025年度业绩快报，营业总收入同比增长122.60%，两产品纳入国家医保推动销售放量。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030200001177.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688192"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616843066","title":"每周股票复盘：迪哲医药（688192）2025年营收增122.60%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616843066","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616843066?lang=zh_cn&edition=full","pubTime":"2026-03-01 02:26","pubTimestamp":1772303172,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘，迪哲医药报收于50.9元，较上周的53.85元下跌5.48%。本周，迪哲医药2月24日盘中最高价报54.49元。本周关注点来自业绩披露要点：迪哲医药2025年营业总收入80,113.56万元，同比增长122.60%。来自公司公告汇总：迪哲医药完成定向增发，募集资金净额17.73亿元。公司公告汇总迪哲医药发布2025年度业绩快报，营业总收入80,113.56万元，同比增长122.60%；归属于母公司所有者的净利润为-76,331.12万元，亏损同比减少8,264.51万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030100000818.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688192"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614857527","title":"迪哲医药（688192）披露2025年度业绩快报公告，2月27日股价上涨1.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614857527","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614857527?lang=zh_cn&edition=full","pubTime":"2026-02-27 23:00","pubTimestamp":1772204446,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘，迪哲医药报收于50.9元，较前一交易日上涨1.17%，最新总市值为236.5亿元。该股当日开盘50.31元，最高51.03元，最低49.56元，成交额达7101.84万元，换手率为0.3%。近日，迪哲医药发布2025年度业绩快报，营业总收入80,113.56万元，同比增长122.60%；归属于母公司所有者的净利润为-76,331.12万元，亏损同比减少8,264.51万元。报告期内完成定向增发，募集资金净额17.73亿元，总资产和净资产显著增长。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022700042920.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688192","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1777842298044,"stockEarnings":[{"period":"1week","weight":-0.0021},{"period":"1month","weight":0.0463},{"period":"3month","weight":-0.0053},{"period":"6month","weight":-0.1099},{"period":"1year","weight":-0.0209},{"period":"ytd","weight":-0.0156}],"compareEarnings":[{"period":"1week","weight":0.0046},{"period":"1month","weight":0.0566},{"period":"3month","weight":-0.0014},{"period":"6month","weight":0.0398},{"period":"1year","weight":0.2541},{"period":"ytd","weight":0.0361}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"迪哲(江苏)医药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"10895人(较上一季度增加8.82%)","perCapita":"42332股","listingDate":"2021-12-10","address":"江苏省无锡市新吴区和风路26号汇融商务广场C栋404、405、416室","registeredCapital":"46516万元","survey":" 迪哲(江苏)医药股份有限公司的主营业务是专注于肿瘤、血液系统疾病领域创新疗法的研究、开发和商业化。公司的主要产品是舒沃哲、高瑞哲。公司获第七批国家级专精特新“小巨人”企业认定。此外，公司首款源头创新产品舒沃哲的研发及产业化项目，荣获江苏省科技进步奖一等奖。","listedPrice":52.58},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"迪哲医药(688192)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供迪哲医药(688192)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"迪哲医药,688192,迪哲医药股票,迪哲医药股票老虎,迪哲医药股票老虎国际,迪哲医药行情,迪哲医药股票行情,迪哲医药股价,迪哲医药股市,迪哲医药股票价格,迪哲医药股票交易,迪哲医药股票购买,迪哲医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"迪哲医药(688192)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供迪哲医药(688192)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}